Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split is part of the Company's plan to regain compliance with Nasdaq listing requirements.
The split-adjusted trading on the Nasdaq Capital Market is set to begin on August 18, 2025.
Reverse Stock Split
Company is effecting a 1 for 3 reverse stock split to maintain Nasdaq market listing.
Board Approval
The reverse stock split was approved by the Board of Directors and shareholders.
Share Reduction
Outstanding common stock will be reduced from 4.77 million shares to approximately 1.59 million.
Fractional Shares
No fractional shares will be issued; stockholders will receive cash instead.
CEO Comment
Interim CEO highlights the importance of Nasdaq listing for shareholder value.
- The reverse stock split aims to enhance the company's visibility and credibility on the Nasdaq market.
- The reduction in outstanding shares may lead to increased stock price due to improved demand.
- The compliance with Nasdaq listing requirements is crucial for the company's future growth and investor confidence.
The reverse stock split by Entero Therapeutics, Inc. signifies a strategic move towards maintaining the Nasdaq market listing and enhancing shareholder value. It reflects the company's commitment to meeting regulatory standards and fostering investor trust.